Evidence guide · US
Oxytocin tablets for stress, mood and sleep: what the evidence shows
A US telehealth brand now sells compounded oxytocin tablets for stress, mood, sleep and intimacy. What nasal-spray trials, a few under-the-tongue studies and the safety data show, and why the evidence for a daily tablet is insufficient.
Review type: research summary. This page summarises published research and product labels, cited below.
On November 17, 2026 Noom launched OpenRx, a US brand selling clinician-prescribed compounded peptides. Its launch line-up includes an oxytocin tablet that dissolves in the mouth, described in the press release as supporting intimacy, and a second tablet that combines oxytocin and the peptide PT-141 with tadalafil for sexual health. Noom's help page for its oxytocin tablet goes further: it says compounded oxytocin "may help support stress relief, mood, and sleep", at one tablet a day.
Short answer: oxytocin is a hormone, and the licensed medicines that contain it are injections used in labor and after birth. Most research on oxytocin for anxiety, mood and sleep used a nasal spray, often as a single dose in a laboratory, and the larger, longer trials, in autism and alcohol use disorder, were negative. The under-the-tongue route rests on a handful of single-dose studies from one research group, and none of them measured stress, mood or sleep over days or weeks. Short-term research doses look well tolerated. Daily nasal use has been followed for 24 weeks; daily tablets have not.
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies, or good studies in other groups of people), Insufficient (too little human research to judge) and Evidence of harm.
What oxytocin is
Oxytocin is a small peptide hormone made of nine amino acids. The US prescribing information for Pitocin, the approved oxytocin injection, describes it as an injection or infusion used to start or strengthen contractions in labor when there is a medical reason, and to control bleeding after birth. The label says oxytocin has a plasma half-life of about 1 to 6 minutes, and that it has pressor and antidiuretic properties that may become apparent at large doses, which the label says are thought to arise because oxytocin and vasopressin differ in only two of the eight amino acids. In the UK, the British National Formulary lists oxytocin for inducing and strengthening labor, at cesarean section, for bleeding after birth and for incomplete, inevitable or missed miscarriage, mainly by intravenous injection or infusion. Neither source lists stress, mood or sleep as a use.
Anxiety and stress: what the trials show
Most human studies gave oxytocin as a nasal spray, often at 24 international units (IU). A 2013 meta-analysis of 19 clinical trials covering autism, social anxiety, postnatal depression, obsessive-compulsive problems, schizophrenia, borderline personality disorder and post-traumatic stress found a combined effect size of d = 0.32 across 304 participants. Only the autism trials showed a significant combined effect on their own (d = 0.57, 68 participants).
The largest autism trial since then was negative. In SOARS-B, published in the New England Journal of Medicine in 2021, 290 children and adolescents aged 3 to 17 were randomized to intranasal oxytocin (target 48 IU a day) or placebo for 24 weeks. Social withdrawal scores fell by 3.7 points with oxytocin and 3.5 points with placebo, a difference of -0.2 (95% CI -1.5 to 1.0). Secondary outcomes generally did not differ, and adverse events were similar in both groups.
In social anxiety disorder, a 2009 trial gave 25 people 24 IU of oxytocin or placebo alongside exposure therapy. The oxytocin group rated their appearance and speech performance more positively as sessions progressed, but symptom reduction at the end of treatment was similar in both groups. A 2026 multisite trial gave 100 adults with alcohol use disorder up to 70 IU a day of intranasal oxytocin or placebo for 12 weeks. There was no significant difference in heavy drinking days, and no significant difference in craving, mood, sleep or pain. The oxytocin group scored lower on anger and physical aggression at the end of treatment.
For low mood, a 2025 meta-analysis of oxytocin added to psychotherapy included 13 trials with 518 participants, four of them in the pooled analysis. Combined treatment reduced depressive symptoms (d = -1.58, 95% CI -3.15 to -0.01), with no significant effect on psychiatric symptoms (d = 0.00) or social functioning (d = 0.21, 95% CI -0.07 to 0.49). The authors list differences between trials and small samples as limitations. None of these trials used oxytocin on its own as a daily wellness product.
Two 2016 reviews in Biological Psychiatry urge caution about the whole field. Walum and colleagues concluded that intranasal oxytocin studies are generally underpowered and that there is a high probability that most published findings do not represent true effects. Leng and Ludwig reported that very little of an intranasal dose appears to reach the fluid around the brain, while levels in the blood rise well above normal.
Tablets and under-the-tongue oxytocin
Human research on oxytocin taken by mouth comes mainly from one research group: Keith Kendrick and colleagues at the University of Electronic Science and Technology of China in Chengdu. In a 2021 trial, 80 men received 24 IU of oxytocin as a spray on the tongue, compared with 138 people given 24 IU by nasal spray. The oral dose increased arousal ratings for faces and brain reward responses, while the nasal dose reduced amygdala responses: the two routes pushed in opposite directions. A 2022 study in 80 healthy men found that 24 IU by mouth reduced state anxiety after an attention task, similar to the group's earlier nasal-spray results. A second 2022 study gave adult men 24 IU in a medicated lollipop and found it raised blood oxytocin about as much as a spray on the tongue, but less than a nasal spray. A 2023 study in 70 women found that oral oxytocin raised blood levels and altered brain responses to emotional faces.
These were single doses, given to healthy volunteers, measured in laboratory tasks over minutes, using sprays and lollipops rather than a compounded daily tablet. None measured stress, mood or sleep in daily life, and no study in this set followed people taking oxytocin by mouth every day for weeks.
Sleep
The sleep evidence is thin. In a 2022 study, 80 couples (160 people) used 32 IU of intranasal oxytocin or placebo each day for five days and rated their sleep each morning. People given oxytocin reported higher sleep quality, with stronger effects in women. The trial was registered as a study of couple interaction and wound healing, and the authors note that these sleep analyses were not preregistered. The 2026 alcohol trial found no difference in sleep. No trial has studied oxytocin tablets for sleep.
Safety
A 2011 systematic review of 38 randomized trials from 1990 to 2010 covered 1,529 participants (79% male) given 18 to 40 IU of intranasal oxytocin, mostly as single doses. Side effects did not differ from placebo, and the authors concluded oxytocin was not associated with adverse outcomes for short-term use in controlled research settings. They also found three case reports of adverse reactions linked to misuse and longer-term use. A 2025 review of nine trials in 331 adults aged 60 and over, at 24 to 72 IU, found adverse effects were mostly mild, and noted that it may not reflect long-term use.
The medicine labels describe hospital use at much higher exposure. The BNF warns that prolonged high-dose intravenous oxytocin with large volumes of fluid may cause water intoxication with low sodium, lists arrhythmias, headache, nausea and vomiting as common or very common side effects, and advises caution in people with latex allergy or intolerance. How these risks apply to a daily tablet has not been studied. Because oxytocin is used to start contractions in labor, ask a doctor before using any oxytocin product if you are or could be pregnant.
Compounded medicines carry their own uncertainty. The FDA says compounded drugs are not FDA-approved, so it does not verify their safety, effectiveness or quality before they are marketed, and that poor compounding practices can lead to a drug containing too much or too little active ingredient. The combination tablet also contains tadalafil, the active ingredient in Cialis. The Cialis label says it must not be used by anyone taking any form of organic nitrate, because it increases the blood-pressure-lowering effect of nitrates, or with guanylate cyclase stimulators such as riociguat.
Evidence grades
- Intranasal oxytocin for anxiety and stress-related conditions: Limited. The trials are small and mixed, and the social anxiety trial did not reduce symptoms more than placebo.
- Oxytocin added to talking therapy for low mood: Limited. Four pooled trials, with a wide confidence interval.
- Oxytocin for sleep: Insufficient. One five-day nasal-spray study with analyses that were not preregistered.
- Daily oxytocin tablets or under-the-tongue doses for stress, mood or sleep: Insufficient. No trials of daily use.
- Safety: short-term research doses showed no consistent excess of side effects over placebo; daily nasal use has been followed for up to 24 weeks, and longer use has not.
Our view
The evidence does not support taking a daily oxytocin tablet for stress, mood or sleep. The research behind oxytocin's reputation as a calming, bonding hormone used nasal sprays, mostly single doses, and its larger, longer trials, in autism and alcohol use disorder, did not show a benefit. The oral data are a few laboratory studies from one group, and in one of them the oral and nasal routes pushed in opposite directions. Noom's own materials describe the same tablet as supporting intimacy in one place and stress, mood and sleep in another, and neither use has been studied in a trial of the tablet.
- Do not treat oxytocin as a supplement. It is a prescription hormone, and compounded versions are not approved for stress, mood or sleep.
- Do not buy oxytocin sold as a research chemical or 'not for human use'. Its contents and dose are unknown.
- If stress, low mood or poor sleep last more than a few weeks, see a doctor, who can look for causes and discuss treatments with trial evidence.
- If you are prescribed oxytocin, tell the prescriber about every other medicine you take, especially nitrates if the product also contains tadalafil, and report side effects.
US rules
Noom's oxytocin tablets are compounded by pharmacies on prescription. The FDA says compounded drugs are not FDA-approved, that consumers buying them through online pharmacies and telehealth platforms may not know which compounder made the drug, and that prescription drug promotion by or on behalf of compounders must be truthful, non-misleading and accurate. Ask your doctor whether an FDA-approved treatment fits your situation before choosing a compounded one, and report a suspected side effect from a drug through FDA's MedWatch program.
FAQ
Does oxytocin help with stress or anxiety?
Some small nasal-spray studies report short-term effects, but clinical trials are mixed. A 2009 social anxiety trial found no difference in symptom reduction, and a 2026 alcohol trial of 100 adults found no difference in mood or sleep.
Do oxytocin tablets work under the tongue?
Single doses on the tongue or in a lollipop raised blood oxytocin and changed responses in laboratory tasks in a few studies from one research group. No trial has studied a daily oxytocin tablet for stress, mood or sleep.
Can oxytocin help you sleep?
One five-day study in couples found higher self-rated sleep quality with an oxytocin nasal spray, but those analyses were not preregistered, and a 12-week trial found no difference in sleep. The evidence is insufficient.
Is compounded oxytocin approved?
No. The FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed. Approved oxytocin products are injections used in labor and after birth.
Sources
These are the documents this page relies on.
- Noom launches OpenRx, a new peptide and preventive health brand (press release, November 17, 2026)Noom
- Oxytocin Peptide (Noom help center page)Noom
- Pitocin (oxytocin) injection: US prescribing information (DailyMed, effective May 5, 2026)Par Health via DailyMed, US National Library of Medicine
- Oxytocin: indications, important safety information, cautions and side effectsBritish National Formulary (BNF), NICE
- Bakermans-Kranenburg MJ, van IJzendoorn MH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry. 2013;3:e258Translational Psychiatry (PubMed 23695233)
- Sikich L, Kolevzon A, King BH, et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med. 2021;385(16):1462-1473New England Journal of Medicine (PubMed 34644471)
- Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009;34(6):917-923Psychoneuroendocrinology (PubMed 19246160)
- Tiouririne NA, Legan JA, Devine E, et al. Intranasal oxytocin for alcohol use disorder: a randomized, double-blind, placebo-controlled multisite trial assessing efficacy and safety. Alcohol Clin Exp Res. 2026;50(7):e70326Alcohol, Clinical and Experimental Research (PubMed 42458234)
- Pérez-Arqueros V, Soler J, Schmidt C, Vega D, Pascual JC. Could intranasal oxytocin enhance the effects of psychotherapy in individuals with mental disorders? A systematic review and meta-analysis. Psychoneuroendocrinology. 2025;171:107206Psychoneuroendocrinology (PubMed 39366103)
- Walum H, Waldman ID, Young LJ. Statistical and methodological considerations for the interpretation of intranasal oxytocin studies. Biol Psychiatry. 2016;79(3):251-257Biological Psychiatry (PubMed 26210057)
- Leng G, Ludwig M. Intranasal oxytocin: myths and delusions. Biol Psychiatry. 2016;79(3):243-250Biological Psychiatry (PubMed 26049207)
- Kou J, Lan C, Zhang Y, et al. In the nose or on the tongue? Contrasting motivational effects of oral and intranasal oxytocin on arousal and reward during social processing. Transl Psychiatry. 2021;11:94Translational Psychiatry (PubMed 33542175)
- Zhuang Q, Zheng X, Yao S, et al. Oral administration of oxytocin, like intranasal administration, decreases top-down social attention. Int J Neuropsychopharmacol. 2022;25(11):912-923International Journal of Neuropsychopharmacology (PubMed 36053298)
- Xu D, Li Q, Zhuang Q, et al. Oro-mucosal administration of oxytocin using medicated lollipops alters social attention, similar to intranasal and lingual routes: implications for therapeutic use. Front Neurosci. 2022;16:1022101Frontiers in Neuroscience (PubMed 36389233)
- Lan C, Chen Y, Zhang Y, et al. Oral oxytocin facilitates responses to emotional faces in reward and emotional-processing networks in females. Neuroendocrinology. 2023;113(9):957-970Neuroendocrinology (PubMed 37231816)
- Doerr JM, Klaus K, Troxel W, et al. The effect of intranasal oxytocin on the association between couple interaction and sleep: a placebo-controlled study. Psychosom Med. 2022;84(6):727-737Psychosomatic Medicine (PubMed 35472193)
- MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011;36(8):1114-1126Psychoneuroendocrinology (PubMed 21429671)
- Sawares A, Olver J, Morcos M, Norman T. Oxytocin in old age psychiatry: a systematic review of the safety of using intranasal oxytocin in older adults. Australas Psychiatry. 2025;33(1):33-44Australasian Psychiatry (PubMed 39474844)
- Compounding and the FDA: questions and answersUS Food and Drug Administration
- Cialis (tadalafil) tablets: US prescribing information, section 4 (DailyMed, effective June 3, 2026)Eli Lilly and Company via DailyMed, US National Library of Medicine
- MedWatch: the FDA safety information and adverse event reporting programUS Food and Drug Administration